MannKind Corp (MNKD) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.24
• Market Cap: $1.56B
• P/E Ratio: 50.70
• EPS: $0.10
• 52-Week High: $6.51
• 52-Week Low: $3.29

Market Sentiment

MannKind Corp currently has a Neutral sentiment score of 0.02.

About MannKind Corp

MannKind Corporation is a biopharmaceutical innovator based in Westlake Village, California, specializing in inhaled therapeutics for endocrine disorders and orphan lung diseases. Utilizing its proprietary Technosphere® platform, the company markets Afrezza, an inhaled insulin designed to enhance glycemic control for diabetes patients, thereby addressing critical unmet medical needs. Committed to pioneering advanced pulmonary delivery systems, MannKind is positioned to significantly improve t...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for MannKind Corp and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does MNKD pay dividends?

MannKind Corp (MNKD) does not currently pay a regular dividend.

What is MNKD's P/E ratio?

MannKind Corp has a price-to-earnings (P/E) ratio of 50.70.

What is MNKD's market cap?

MannKind Corp (MNKD) has a market capitalization of $1.56B with a current stock price of $3.24.